Scientific Sessions 2025  /  Defining Success in EP Clinical Trials  /  VANISH2 Trial: Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia
Logo

American Heart Association

  72
  0

Final ID:

VANISH2 Trial: Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia

  • Sapp, John  ( QEII HEALTH SCIENCES CENTRE , Halifax , Nova Scotia , Canada )
    • Author Disclosures:
    John Sapp: DO have relevant financial relationships ; Consultant:Varian:Active (exists now) ; Research Funding (PI or named investigator):Johnson & Johnson:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Defining Success in EP Clinical Trials

Friday, 11/07/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Mortality or bust: what makes for a meaningful VT trial outcome?

Stevenson William, Gerstenfeld Edward

The ADVENT Trial. Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden

Reddy Vivek, Mansour Moussa

More abstracts from these authors:
Acceptability and Effectiveness of a Novel, Video-Based CPR and AED Education Program in Canadian Schools

Allan Katherine, Dhillon Santokh, Mcculloch Holly, Ruether Kim, Zotzman Jeanine, Blanchard Ian, Janczyszyn Mike, Wong Natalie, Oneil Emma, Sapp John

In-Depth: VANISH2: Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy

Sapp John

You have to be authorized to contact abstract author. Please, Login
Not Available